The present study aimed to estimate the serum levels of soluble tumor necrosis factorrelated apoptosis-inducing ligand (sTRAIL) in patients with systemic lupus erythematosus (SLE) 
INTRODUCTION
Apoptosis (programmed cell death) is an active physiological process that leads to the ordered destruction of cells without the release of intracellular contents which would cause an inflammatory reaction and tissue damage into the extracellular environment. It is fundamental to maturation and homeostasis of the immune system. Apoptosis can be induced passively, through lack of essential survival signals, or actively, through ligand induced trimerization of specific death receptors of the tumor necrosis factor (TNF) receptor family, such as Fas, the TNF receptor, or the TNF related apoptosis inducing ligand receptor (1) . TNF-related apoptosis-inducing ligand (TRAIL, APO-2 ligand) is a transmembrane (type II) glycoprotein (2) . The extracellular domain of TRAIL is homologous to that of other TNF superfamily members and shows a homotrimeric subunit structure. Like TNF and FasL, TRAIL also exists physiologically in a biologically active soluble homotrimeric form (3) . TRAIL can interact with five different receptors, namely two agonistic receptors called DR4/TRAIL-R1 and DR5/TRAIL-R2 (referred to as TRAIL-R1 and -R2, respectively), two membraneanchored decoy receptors designated DcR1/TRAIL-R3 and DcR2/TRAIL-R4 (referred to as TRAIL-R3, and -R4, respectively), and a soluble decoy receptor known as osteoprotegerin (OPG) (4) . The affinities of TRAIL-R3 and -R4 for TRAIL at physiological temperatures are 50-100-fold lower than those between TRAIL and its cognate receptors TRAIL-R1 and -R2 (5) . TRAIL triggers apoptosis through interaction with the death receptors TRAIL-R1 and -R2 that contain a cytoplasmic death domain and can induce apoptosis through the activation of caspases upon ligation with a TRAIL ligand. Nevertheless, the binding of TRAIL to these TRAIL receptors can also activate the transcription factor NFκB, which is known to control cell proliferation (6) . Indeed, although TRAIL is known to induce apoptosis in tumor cells, TRAIL has also been shown to promote endothelial cell proliferation (7) . Thus, depending on the cellular system, TRAIL is capable of initiating apoptosis or cell survival (8) . There are several indications that TRAIL could be involved in the pathophysiology of autoimmune diseases in general and SLE in particular. In patients with multiple sclerosis, FasL and TRAIL are upregulated in peripheral blood mononuclear cells (9) . In patients with Sjögren's syndrome TRAIL-R1 and TRAIL-R2 are strongly expressed on the ductal epithelial cells in the salivary glands (10) . Kaplan et al. . The aetiology of SLE is complex. Multiple susceptibility genes and environmental factors are implicated in the initiation and perpetuation of the activation of T and B lymphocytes. Also, Spontaneous remission or improvements in the course of the disease are common in patients with SLE (13) . This study aimed to estimate the serum levels of soluble TRAIL in patients with SLE and to compare these levels to that estimated in patients with other autoimmune diseases and to control levels. All study participants gave venous blood samples that were allowed to clot and centrifuged to separate serum which is kept frozen at -80 o C till assayed for sTRAIL concentration using ELISA technique as follows: a monoclonal antibody specific for sTRAIL was coated onto the wells of the microtitre strips. An aliquot of 100 µl of undiluted serum was pipetted in duplicate into the wells. During the first incubation, the sTRAIL antigen and a biotinylated monoclonal antibody specific for sTRAIL were simultaneously incubated for three hours at room temperature (18-25°C). After washing, the enzyme streptavidin-poly horseradish peroxidase was added. After incubation for 30 minutes and washing to remove unbound enzyme, a substrate solution was added to the bound enzyme to induce a coloured reaction product. The optical density (OD), reflecting the intensity of the product, was measured using spectrophotometer at 450 nm as the primary wavelength and 650 nm as the reference wavelength. Linear calibration curves were made using standard TRAIL (0-3000 pg/ml), provided with the kit. The amount of sTRAIL in the serum samples was determined by extrapolating OD values to TRAIL concentrations using the calibration curves. The minimum detectable dose was 64 pg/ml. The ELISA was found to be specific for TRAIL; cross reactivity with TNF-α was absent and the signal could be blocked specifically by the addition of soluble TRAIL receptors (18) .
PATIENTS & METHODS

Statistical analysis
Obtained data were presented as mean±SD, ranges, numbers and ratios. Results were analyzed using paired Ztest and Chi-square test. Possible relationships were investigated using Pearson linear regression. Statistical analysis was conducted using the SPSS (Version 10, 2002) for Windows statistical package. P value <0.05 was considered statistically significant.
RESULTS
The study included 50 SLE patients; 39 females and 11 males with mean age of 45.6±12.3; range: 15-72 years and 15 patients with RA; 11females and 4 males with mean age of 45.3±8.2; range: 29-59 and 15 patients with WG; 10 females and 5 males with mean age of 41.6±12.5; range: 24-63 years. There was a nonsignificant difference between studied patients as regards age and sex distribution. Also, 10 control subjects; 7 females and 3 males with mean age of 42.7±13; range: 26-67 years were enrolled in the study.
Clinical evaluation of SLE patients using SLEDAI score defined 27 patients with inactive disease with mean SLEDAI score of 2±0.2; range: 1.5-2.2 and 23 patients with active disease with mean SLEDAI score of 9.96±0.63; range: 8.9-11. There was a non-significant difference between patients with active and inactive SLE as regards age and sex distribution.
Mean blood levels of C3 and C4 were significantly (p<0.001) decreased in patients with active SLE compared to those with inactive disease. Also, both total and differential leucocytic counts were significantly lower in patients with active compared to those with quiescent disease and 5 patients; 3 had active disease and 2 had inactive disease were neutropenic. On contrary, mean CRP level and antidsDNA antibodies levels were significantly (p<0.001) higher in patients with active disease (Table 1) .
Mean serum levels of sTRAIL were significantly higher in SLE patients, irrespective to the disease activity compared to serum levels estimated in controls (P 1 =0.005) and in RA and WG patients (P 2 & P 3 =0.001). On contrary, serum sTRAIL levels estimated in RA and WG were non-significantly higher compared to control level (P 1 >0.05) with a non-significantly higher levels in RA patients compared to levels estimated in WG patients (P 2 >0.005). Patients with inactive SLE had a significantly (P 4 =0.002) higher serum levels of sTRAIL compared to levels estimated in patients with active SLE, (Table 2, Fig. 1 ). Serum sTRAIL showed a negative significant correlation with SLEDAI score and laboratory parameters of SLE activity (Table 3, Fig. 2 ). . TRAIL is a member of the TNF gene superfamily, which induces apoptosis through engagement of death receptors. TRAIL is unusual as compared to the other cytokines of this family, as it interacts with a complex system of receptors. Moreover, with respect to other members of the TNF superfamily, such as CD95L and TNF-alpha, TRAIL has generated great interest as a potential tumor-specific cancer therapeutic because as a stable soluble trimer it selectively induces apoptosis in many transformed cells but not in normal cells (24) . The current study aimed to estimate the serum levels of soluble TRAIL in patients with SLE and to compare these levels to that estimated in patients with other autoimmune diseases and to control levels. Preliminary laboratory investigations defined significantly lower total and differential leucocytic counts in patients with active compared to those with quiescent disease and 5 patients were neutropenic.
DISCUSSION
These findings point to increased apoptosis of leucocytes and neutrophils during activity phase of disease and agreed with results of cellline study of Ren et al.
(22) who found that the percentage of apoptotic PMNs from patients with SLE was significantly higher than that of PMNs from healthy subjects and increased progressively with time of incubation and that serum from patients with SLE accelerated the rate of apoptosis in and secondary necrosis of PMNs from healthy subjects and macrophages from SLE patients were less capable of phagocytosing apoptotic PMNs compared with macrophages obtained from controls. They concluded that the observed increase of apoptotic PMNs and macrophages and the poor ability of macrophages from patients with SLE to phagocytose apoptotic bodies may indicate an impaired clearance mechanism, which may be mediated by factors in a patient's serum.
Various studies tried to explore the accelerated neutrophil apoptosis in active SLE; Armstrong et al.
(25) found neutrophils from SLE patients display resistance to the apoptosis-inhibiting effects of G-CSF and possibly GM-CSF, and appear more susceptible to the apoptosis-inducing action of TNF-α, the greatest resistance being observed in the more neutropenic patients. In another study, Armstrong et al.
(26) attributed this to increased levels of anti-dsDNA antibodies and found polyclonal anti-dsDNA antibody isolated from the serum of patients with active SLE accelerates apoptosis in neutrophils from SLE patients as compared with neutrophils from healthy control or rheumatoid arthritis subjects. In support of such observation, in the current study there was a significant increase of blood levels of anti-dsDNA antibodies in patients with active compared to those with inactive SLE.
In another explanation, Lit et al.
(27) found a correlation of raised plasma concentration and ex vivo production of inflammatory chemokines with SLE disease activity, and their association with IL-18, supports the view that chemotaxis of Th1/Th2 lymphocytes and neutrophils is important in SLE pathogenesis.
Mean serum levels of sTRAIL were significantly higher in SLE patients, irrespective to the disease activity compared to serum levels estimated in controls (P 1 =0.005) and in RA and WG patients (P 2 & P 3 =0.001). On contrary, serum sTRAIL levels estimated in RA and WG were non-significantly higher compared to control level (P 1 >0.05) with a non-significantly higher levels in RA patients compared to levels estimated in WG patients (P 2 >0.005). These findings illustrated the specificity of increased serum levels of sTRAIL to SLE disease as the levels estimated in patients with other autoimmune diseases were nonsignificantly different from control levels and in-between both types of diseases. Moreover, the obtained data spotted light on a possible role of TRAIL in pathogenesis of SLE.
These data go in hand with Komatsuda et al.
(28) who found the mean TRAIL mRNA expression level and serum sTRAIL concentration in SLE patients were significantly higher than those in healthy controls. They concluded that increased expression of TRAIL mRNA in peripheral blood mononuclear cells (PBMC) closely correlates with SLE activity and suggests an important role for TRAIL in the pathogenesis of SLE. Also, Castellino et al.
(29) found serum TRAIL and OPG concentrations in SLE patients were significantly higher than those in healthy volunteers.
The origin of the increased serum sTRAIL levels in SLE patients is still a mater of controversy; peripheral blood lymphocytes are activated in SLE patients even during clinically inactive disease; T cell activation has been found to contribute to increased expression of TRAIL and other apoptotic ligands on lupus T cells isolated from SLE patients (11) . Furthermore, in vitro studies reported that TRAIL could be released from stimulated monocytes (30) as well as from activated T cells, (31) . These findings are supported by increased gene expression of TRAIL and its decoy receptors in peripheral blood mononuclear cells from SLE patients (32) . This overexpression could result in increased TRAIL concentrations.
Interferons (IFN-α, β and γ) might also play an important role in increased sTRAIL levels; overexpression of IFN induced genes occurs in PBMC of SLE patients. This is of interest as human monocytes rapidly express TRAIL following activation with IFN (33) . Kirou et al.
found SLE patients with a high IFN-α score had a significantly higher SLEDAI scores and disease activity, as measured by lower C3 levels, hemoglobin levels, absolute lymphocyte counts, and albumin levels, and a higher dsDNA titer. In support of these data, we reported significantly lower C3 and C4 levels in patients with active disease compared to levels estimated in patients with inactive disease. Also, Bijl et al. (35) found that reduced uptake of apoptotic cells by monocytesderived macrophages from patients with SLE and subsequent disease activity is serum dependent and associated with decreased levels of C4 and C3.
There was a negative significant correlation between serum sTRAIL and leucocytic and neutrophil counts, such data indicated a possible role for TRAIL in neutrophil apoptosis associated with SLE activity and agreed with Matsuyama et al.
(36) who found serum TRAIL levels in SLE patients with neutropenia were significantly higher than those of SLE patients without neutropenia and healthy volunteers and showed a significant negative correlation with neutrophil counts in SLE patients.
Patients with inactive SLE had a significantly (P 4 =0.002) higher serum levels of sTRAIL compared to levels estimated in patients with active SLE. This could be attributed to binding of TRAIL to its receptors, distribution of sTRAIL throughout the body, or decreased TRAIL production. Binding of sTRAIL to its death receptors could lead to increased apoptosis of monocytes and lymphocytes. This is supported by the reported significantly decreased monocyte and lymphocyte counts found in patients with active SLE It could be concluded that TRAIL has a possible role in pathogenesis and intiation of activity of SLE and estimation of serum sTRAIL could be used as a specific marker for differentiation between SLE from other autoimmune diseases and between patients with active and inactive disease. 
